Clinical Trials · NCT06542874

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

CompletedPhase 2Amycretin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
448
Start date
Aug 2024
Locations
137 sites, 11 countries
Primary endpoint
Change in HbA1c
View Amycretin compound reference